- $992.16m
- $495.09m
- $32.33m
Brief: Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
Brief: Verve Therapeutics Q1 Collaboration Revenue USD 32.976 Million
U.S. RESEARCH ROUNDUP- CNB Financial, Disney, Triumph Group
U.S. STOCKS ON THE MOVE-StoneX, US automakers, Johnson & Johnson
U.S. STOCKS ON THE MOVE-Intel, Orla Mining, Biogen
U.S. STOCKS ON THE MOVE-Pfizer, ConocoPhillips, NextDecade
Verve rises after initial data from early-stage study for gene editing therapy
Brief: Verve Therapeutics Receives U.S. FDA Fast Track Designation For Verve-102, An In Vivo Base Editing Medicine Targeting Pcsk9
Brief: Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Brief: Verve Therapeutics Q4 EPS USD -0.58
Brief: Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Verve Therapeutics Q3 EPS USD -0.59
Brief: Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Verve Therapeutics Q2 EPS USD -0.59
Brief: Verve Therapeutics Increased Size Of Board To Nine Members
Brief: Millennium Management Llc Reports 5.1% Passive Stake In Verve Therapeutics Inc As Of June 21 - SEC Filing
Brief: Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Verve Therapeutics Announces Leadership Update
Brief: Verve Therapeutics Q1 EPS USD -0.59